ESR1 and breast neoplasm: The vast majority of breast tumors bearing CCND1 amplification are readily defined as ER positive, are luminal B by gene expression analysis, and overexpress cyclin D1 protein; most notably, patients with CCND1 amplified tumors show reduced survival times and associations to treatment resistance.